查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1978935

植物生物技術設備市場：按設備類型、技術、工作流程階段、應用和最終用戶分類－2026年至2032年全球市場預測

Plant Biotechnology Equipment Market by Instrument Type, Technology, Workflow Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，植物生物技術設備市場價值將達到 159 億美元，到 2026 年將成長至 179.1 億美元，到 2032 年將達到 370.5 億美元，複合年成長率為 12.84%。

主要市場統計數據
基準年 2025 159億美元
預計年份：2026年 179.1億美元
預測年份 2032 370.5億美元
複合年成長率 (%) 12.84%

簡要概述了技術、營運和商業性因素在重組植物生物技術設備採購和實驗室工作流程中的整合。

隨著創新者、服務供應商和研究機構追求更高的通量、更強的可重複性和更整合的工作流程，植物生物技術設備市場正在快速發展。本文總結了推動基因工程、定序和表現型分析等實驗室和生產設備投資和應用成長的因素，並概述了重塑整個領域採購、營運和協作的因素。

模組化平台、循環消耗品、數據驅動型服務以及對永續性的重視，正在從根本上重塑設備策略和供應商差異化。

植物生物技術儀器市場正經歷一系列相互關聯的變革，這些變革涵蓋了從實驗室到現場應用、從儀器設計到商業服務模式的各個方面。首先，模組化和工作流程整合正在重新定義產品藍圖。在實驗室中，能夠實現樣品製備、定序或合成以及下游分析之間快速轉換的平台正日益受到青睞。這種對資料和材料無縫流動的重視促使供應商提供捆綁式解決方案、更強大的軟體整合以及預檢驗通訊協定，從而縮短結果獲取時間並簡化監管驗證流程。

我們將評估美國最近的關稅措施對整個價值鏈的籌資策略、製造地、消耗品供應的連續性以及採購風險管理的影響。

近期美國關稅及相關貿易措施的累積影響，為植物生物技術設備的採購計畫、供應鏈建構和定價策略帶來了新的變數。在交易層面，零件和成品設備進口關稅的提高可能會壓縮利潤空間或推高終端用戶的標價，迫使企業重新評估籌資策略並探索替代供應管道。因此，採購團隊正在重新評估其供應商組合和規格，並尋求從國內或免稅地區採購零件和子系統。

針對每個工作流程階段，透過細分市場來主導設備子類別、應用需求、技術選項、最終使用者採購行為和優先級，從而指導目標策略。

精確的細分觀點揭示了不同儀器類型、應用、技術、終端使用者和工作流程階段所面臨的獨特機會和挑戰。儀器包括生物反應器、DNA定序儀、微陣列系統和PCR系統，每個類別都呈現各自的子類別發展趨勢。生物反應器正根據生產規模和檢驗要求的不同，分化為一次性使用型和不銹鋼型。 DNA定序儀分為次世代定序（NGS）平台和傳統的Sanger定序系統，其中NGS推動了對高通量檢驗的大部分需求。微陣列系統專注於基因表現分析和SNP分析，每個應用場景都決定了陣列密度和分析需求。 PCR系統已發展為數位PCR和qPCR模式，其中數位PCR因其靈敏度和絕對定量能力而備受青睞。

區域採購週期、監管預期和服務網路要求會影響美洲、歐洲、中東和非洲以及亞太地區的設備部署。

區域趨勢對美洲、歐洲、中東和非洲（EMEA）以及亞太地區的採購週期、監管預期和夥伴關係模式產生顯著影響。在美洲，由研究機構、生物技術Start-Ups和成熟製造商組成的強大生態系統塑造了以整合平台、完善的售後服務和本地試劑供應鏈為重點的需求格局。這種環境也推動了次世代定序和基因編輯工作流程的快速早期應用，而採購決策則受到機構津貼週期和私人投資模式的影響。

競爭格局分析，展示了成熟的平台公司、利基創新者、消費生態系統和服務整合商如何建立長期競爭優勢。

植物生物技術儀器領域的競爭格局呈現出多元化的特點，既有成熟的平台公司，也有專注於創新的專業廠商和垂直整合的供應商，這模糊了儀器供應商和服務供應商之間的界線。成熟的儀器製造商在平台可靠性、處理能力和豐富的耗材生態系統方面展開競爭，而專注於特定領域的供應商則致力於提升靈敏度、小型化和自動化等性能差異化優勢，以解決特定的工作流程瓶頸。這種競爭格局推動著持續的漸進式創新，供應商不斷改進光學、流體控制、熱控制和軟體，以擴大其產品在目標應用領域的普及程度。

為製造商和服務供應商提供切實可行的策略步驟，以增強韌性、深化客戶價值並抓住產品和服務差異化機會。

產業領導企業應採取果斷且具有前瞻性的措施，透過對製造柔軟性、產品架構和客戶參與進行有針對性的投資，將顛覆性趨勢轉化為策略優勢。首先，他們應加快模組化產品設計，以便在不重新設計整個平台的情況下更換受影響的子組件。這將降低關稅造成的供應衝擊風險，並縮短本地化生產所需的認證流程時間。透過模組化設計，企業可以提供可擴展的配置，既能滿足研發實驗室的需求，又能滿足商業規模營運的需求，進而拓展目標應用場景。

我們採用混合研究途徑，結合與關鍵相關人員的訪談、技術產品審查和政策研究，得出檢驗且可操作的見解。

本研究採用三角測量調查方法綜合結果，該方法結合了質性訪談、二手文獻整合以及針對特定產品和政策的研究。關鍵輸入資料包括對學術界、工業界和服務供應商等各領域研究機構負責人、採購專家、設備工程師和商業部門領導者的結構化訪談。這些訪談重點在於採購促進因素、檢驗流程、供應鏈脆弱性以及資料分析在設備部署中的作用。

總結了以下見解，闡述了工作流程整合、供應鏈彈性以及以數據為中心的服務為何能夠推動整個產業的競爭成功。

總之，受技術成熟度、採購預期變化以及地緣政治和貿易因素的驅動，植物生物技術儀器市場正經歷戰略轉型。儀器創新正與軟體主導的分析和以耗材為中心的經營模式融合，競爭焦點也從獨立儀器轉向能夠提供可重複結果的、檢驗的端到端工作流程。這種演變有利於那些不僅擁有技術能力，而且擁有強大的服務網路、檢驗的通訊協定和供應鏈韌性的供應商。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：植物生物技術設備市場：依設備類型分類

  • 生物反應器
    • 一次使用
    • 不銹鋼
  • DNA定序儀
    • 次世代定序
    • 桑格定序
  • 微陣列系統
    • 基因表現
    • SNP分析
  • PCR系統

第9章：植物生物技術設備市場：依技術分類

  • CRISPR工具
    • 質體導入
    • 核糖核蛋白
  • 次世代定序
  • PCR技術

第10章：植物生物技術設備市場各階段工作流程

  • 分析
    • 生物資訊學
    • 數據視覺化
  • 樣品製備
    • DNA萃取
    • 樣品製備
  • 合成
    • 基因合成
    • 寡核苷酸合成

第11章：植物生物技術設備市場：依應用領域分類

  • 基因編輯
  • 基因分析
    • 表達分析
    • 基因型鑒定
  • 表現型分析
    • 影像分析
    • 感測器基座
  • 組織培養
    • 癒傷組織培養
    • 原生質體培養

第12章：植物生物技術設備市場：依最終用戶分類

  • 學術機構
    • 研究中心
    • 大學
  • 生技公司
    • 農業生物技術
    • 製藥和生物技術
  • 合約研究機構
  • 製藥公司

第13章：植物生物技術設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：植物生物技術設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：植物生物技術設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國植物生物技術設備市場

第17章：中國植物生物技術設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • LabRepCo
  • LemnaTec GmbH
  • LGC Limited
  • Merck KGaA
  • Microsil India Pvt. Ltd.
  • Narang Scientific Works Pvt. Ltd.
  • Neu-tec Group Inc.
  • PerkinElmer, Inc.
  • Sartorius AG
  • Shimadzu Corporation
  • Tecan Group Ltd.
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
Product Code: MRR-521BAA36EA76

The Plant Biotechnology Equipment Market was valued at USD 15.90 billion in 2025 and is projected to grow to USD 17.91 billion in 2026, with a CAGR of 12.84%, reaching USD 37.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.90 billion
Estimated Year [2026] USD 17.91 billion
Forecast Year [2032] USD 37.05 billion
CAGR (%) 12.84%

A concise orientation to the converging technological, operational, and commercial forces reshaping plant biotechnology equipment procurement and laboratory workflows

The plant biotechnology equipment landscape is undergoing rapid evolution as innovators, service providers, and research institutions seek higher throughput, greater reproducibility, and more integrated workflows. This introduction synthesizes the drivers behind heightened investment and adoption in laboratory and production equipment used for genetic manipulation, sequencing, and phenotyping, while framing the forces reshaping procurement, operations, and collaboration across the sector.

Adoption trends are being driven by the maturing of gene editing techniques, expanded applications of next generation sequencing, and the increasing reliance on automation and single-use technologies to accelerate experimental timelines. At the same time, tighter regulatory scrutiny, supply chain pressures, and the growing emphasis on data outputs and bioinformatics are reshaping how equipment is specified, validated, and serviced. These dynamics are prompting both incumbents and new entrants to re-evaluate product roadmaps, after-sales service models, and partner ecosystems.

For decision-makers, this introduction serves as an orientation to the essential market forces that influence capital planning and operational design. It highlights the confluence of technological maturation, workflow integration, and the commercial impetus to turn laboratory throughput into reliable, reproducible outputs that support downstream breeding, trait development, and biologics discovery. The remainder of this executive summary builds on these themes to explore strategic shifts, trade-policy impacts, segmentation-specific opportunities, regional differences, competitive behaviors, and recommended actions for leaders seeking to translate capability into sustainable advantage.

How modular platforms, recurring consumables, data-driven services, and sustainability priorities are fundamentally reshaping equipment strategies and vendor differentiation

The landscape for plant biotechnology equipment is being transformed by a set of interconnected shifts that extend from the bench to the field and from instrument design to commercial service models. First, modularization and workflow integration are redefining product roadmaps: laboratories increasingly favor platforms that enable rapid handoffs between sample preparation, sequencing or synthesis, and downstream analysis. This emphasis on seamless data and material flow is encouraging vendors to offer bundled solutions, stronger software integration, and pre-validated protocols that reduce time-to-result and ease regulatory validation.

Second, the rise of precision gene editing methods has shifted demand toward instruments and consumables that support fine-grained control and reproducibility. Tools that facilitate CRISPR workflows, from delivery systems to verification by sequencing, are attracting disproportionate attention, prompting suppliers to optimize instrument compatibility with reagents and analytics. Consequently, consumables and service revenue streams are becoming more central to competitive positioning, as recurring purchases of kits, reagents, and software subscriptions provide predictable value beyond initial instrument sales.

Third, digitization and data-centric service offerings are elevating the role of bioinformatics and cloud-enabled visualization in equipment value propositions. Customers expect vendors to support not only raw data generation but also downstream interpretation, which is driving deeper partnerships between instrument manufacturers and analytics providers. Regulatory and quality management considerations are also catalyzing investments in traceability, electronic lab record integration, and validated data pipelines, which in turn influence purchasing criteria and procurement cycles.

Finally, operational resilience and sustainability are emerging cross-cutting themes that inform design and deployment choices. Single-use systems, energy-efficient thermal modules, and supply-chain transparency are increasingly factored into procurement decisions, as institutions weigh total cost of ownership alongside environmental and compliance imperatives. Taken together, these transformative shifts are reshaping the competitive calculus across instrument categories, applications, and end-user segments, and they underscore the need for vendors and buyers to align product innovation with evolving workflow and policy realities.

Assessing how recent US tariff measures reshape sourcing strategies, manufacturing footprints, consumable supply continuity, and procurement risk management across the value chain

The cumulative impact of recent United States tariffs and related trade measures has introduced new variables into procurement planning, supply chain architecture, and pricing strategies for plant biotechnology equipment. At the transactional level, increased import levies on components or finished instruments can erode margins or push list prices higher for end users, creating pressure to re-evaluate sourcing strategies and to explore alternative supply pathways. Procurement teams are consequently reassessing supplier portfolios and specifications to identify components and subsystems that can be sourced domestically or from tariff-favored jurisdictions.

Beyond immediate cost effects, tariffs influence strategic decisions around manufacturing footprint and supplier relationships. Many manufacturers are conducting scenario planning to determine whether localization, nearshoring, or diversification of contract manufacturers will mitigate future trade exposure. These decisions are informed by considerations of production scale, labor skills, intellectual property protection, and regulatory compliance. In some cases, moving assembly or subassembly closer to key markets reduces tariff vulnerability but introduces new complexities in quality control and supplier development timelines.

Tariffs also have downstream consequences for service and consumable supply chains. Recurring revenue streams tied to reagents, cartridges, and single-use disposables may become subject to the same trade frictions, prompting service providers to secure multiple distribution channels and to negotiate longer-term supply contracts to stabilize availability and pricing for customers. For research institutions and companies with global operations, the uncertainty around effective landed costs can delay capital investments and lengthen procurement cycles, particularly for high-value instruments that require extended validation.

Regulatory and policy responses further compound the landscape. Trade actions can trigger reciprocal measures, induce changes in tariff classification, or accelerate bilateral trade negotiations, each of which alters the competitive dynamics for specific technologies. Consequently, commercial teams must integrate trade-policy monitoring into their market surveillance and risk management processes. Additionally, procurement and R&D leaders are increasingly factoring tariff exposure into product design decisions, opting for more modular architectures that allow substitution of affected components without redesigning whole platforms.

In summary, tariffs act as a strategic stress test that exposes reliance on concentrated suppliers and geographically narrow manufacturing footprints. While the immediate effect is often cost pressure, the longer-term responses-reshoring, diversification, contractual hedging, and design modularity-reshape how instruments are produced, sold, and serviced. Stakeholders that proactively incorporate trade-policy risk into sourcing, pricing, and product strategies can reduce disruption, preserve margins, and maintain service continuity for end users.

Segment-driven clarity on instrument subcategories, application demand, technology choices, end-user procurement behavior, and workflow-stage priorities to guide target strategies

A nuanced segmentation lens reveals differentiated opportunities and constraints across instrument types, applications, technologies, end users, and workflow stages. Instruments span bioreactors, DNA sequencers, microarray systems, and PCR systems, with each category exhibiting distinct subcategory dynamics: bioreactors bifurcate into single-use and stainless steel designs that appeal to different scales of production and validation requirements; DNA sequencers split across next generation sequencing platforms and legacy Sanger systems, with NGS driving much of the demand for high-throughput verification; microarray systems are focused on gene expression versus SNP analysis, where each use case informs array density and interpretation needs; and PCR systems are evolving across digital PCR and qPCR modalities, where digital formats are prized for sensitivity and absolute quantification.

Applications provide another axis of differentiation, spanning gene editing, genetic analysis, phenotyping, and tissue culture. Within gene editing, CRISPR dominates adoption curves alongside TALEN and ZFN for certain niche use cases where delivery constraints or intellectual property considerations influence method selection. Genetic analysis skews toward expression analysis and genotyping, each with unique sample throughput and data interpretation demands. Phenotyping workflows increasingly combine image analysis with sensor-based approaches to capture complex trait data, while tissue culture encompasses callus culture and protoplast culture techniques that require specialized incubators and sterile handling solutions.

Technology-driven segmentation further clarifies where investment and innovation are concentrated. CRISPR toolchains leverage plasmid delivery approaches and ribonucleoprotein methods, each with different implications for instrument compatibility and validation. Next generation sequencing has internal technology splits such as platforms aligned with Illumina-style sequencing chemistries and those more closely associated with Ion Torrent-style semiconductor detection, and buyers often weigh read characteristics, run time, and library preparation demands when selecting platforms. PCR technology differentiates along ddPCR and qPCR paths, with the former favored for high-precision quantification and the latter remaining a workhorse for routine assays.

End-user segmentation highlights the diversity of purchasing drivers and support expectations across academic institutions, biotech companies, contract research organizations, and pharmaceutical companies. Academic institutions frequently procure instruments for open-ended research and training and include research centers and universities with differing budget cycles and service needs. Biotech companies encompass agri biotech and pharma biotech players focused on commercialization and scale-up. Contract research organizations span clinical CRO services and broader CRO offerings that prioritize throughput, validated workflows, and vendor interoperability, while pharmaceutical companies cover biologics and small molecule divisions with distinct regulatory and quality management demands.

Finally, workflow-stage segmentation-analysis, sample preparation, and synthesis-sheds light on where value is realized and how vendors can differentiate. Analysis stages increasingly require integrated bioinformatics and data visualization capabilities to turn raw reads or phenotypic images into actionable insights. Sample preparation covers DNA extraction and library preparation, areas where automation and kit standardization substantially reduce variability. Synthesis spans gene synthesis and oligo synthesis, which underpin many downstream workflows and invite strategic partnerships between instrument makers and oligonucleotide suppliers. By mapping technology and product strategies onto these interlocking segmentation tiers, stakeholders can better prioritize product development, channel strategy, and after-sales services to match the nuanced needs of distinct customer cohorts.

Regional procurement rhythms, regulatory expectations, and service network imperatives that shape equipment adoption across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a profound influence on procurement rhythms, regulatory expectations, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a strong ecosystem of research institutions, biotech startups, and established manufacturers creates a demand profile that favors integrated platforms, robust after-sales service, and local reagent supply chains. This environment also supports rapid early adoption of next generation sequencing and gene editing workflows, while procurement decisions are shaped by institutional grant cycles and private investment patterns.

In Europe, the Middle East & Africa, regulatory harmonization efforts and sustainability commitments are major considerations that inform purchasing criteria, from energy-efficient instrument designs to traceable consumable sourcing. Buyers in these markets often emphasize compliance pathways and documentation that facilitate cross-border research collaborations. Additionally, localized service networks and certified distributors are pivotal for maintaining uptime, particularly for high-throughput sequencing and bioreactor systems used in both academic and industrial settings.

The Asia-Pacific region is marked by rapid capacity expansion, diversified manufacturing bases, and aggressive government support for bioscience capabilities. Demand here spans large-scale agricultural biotech initiatives, contract service expansion, and growing clinical and research sequencing programs. Buyers frequently seek cost-competitive instruments with reliable consumable availability and scalable service agreements. Strategic partnerships with local players and investments in training and support infrastructure are common approaches for vendors seeking durable market presence across this heterogeneous region.

Across all regions, cross-border collaboration, harmonized quality standards, and logistics robustness are recurring themes. Vendors that tailor their go-to-market models to regional procurement rhythms, regulatory idiosyncrasies, and service expectations are better positioned to build long-term customer relationships and to mitigate risks associated with supply interruptions and compliance changes.

Competitive landscape analysis showing how platform incumbents, niche innovators, consumable ecosystems, and service integrators shape long-term advantage

Competitive dynamics in the plant biotechnology equipment space are characterized by a mix of platform incumbents, specialist innovators, and vertically integrated suppliers that blur the lines between instrument vendor and service provider. Established instrument manufacturers compete on platform reliability, throughput, and depth of consumable ecosystems, while niche suppliers focus on performance differentiators such as sensitivity, miniaturization, or automation that address specific workflow bottlenecks. This competitive tension drives continuous incremental innovation as vendors refine optics, fluidics, thermal control, and software to gain adoption in targeted applications.

Concurrently, reagent and consumable suppliers wield outsized influence on customer lock-in and recurring revenue streams. The commercial logic of pairing instruments with proprietary reagents or cartridges supports predictable service income and cements long-term customer relationships. As a result, strategic alliances between platform manufacturers and consumable specialists are common, and some players elect to vertically integrate to capture more of the downstream revenue pool. Services companies and contract research organizations also act as critical intermediaries, offering high-throughput access to technologies for customers that prefer project-based engagement over capital investment.

Market entrants tend to pursue one of two playbooks: differentiation through a narrow technical advance that addresses a specific pain point, or broad platform development that emphasizes compatibility and enterprise integration. The former enables faster market entry and targeted adoption, while the latter demands larger investments in regulatory validation and support infrastructure but offers higher lifetime customer value. Across these approaches, key success factors include robust validation data, clear total cost of ownership narratives, accessible training and support, and transparent compatibility with established workflows and data systems.

Overall, companies that balance innovation with service excellence, that cultivate strong channel partnerships, and that build ecosystems around consumables and analytics are best poised to capture sustainable advantage. Competitive advantage increasingly depends not only on instrument performance but also on the ability to deliver validated, end-to-end workflows that reduce time-to-insight for researchers and developers.

Practical strategic moves for manufacturers and service providers to build resilience, deepen customer value, and seize product and service differentiation opportunities

Industry leaders should take decisive, proactive steps to convert disruptive trends into strategic advantage through targeted investments in manufacturing flexibility, product architecture, and customer engagement. First, accelerate modular product design so that affected subassemblies can be substituted without full platform redesign; this reduces exposure to tariff-driven supply shocks and shortens qualification timelines for localized production. By designing for modularity, firms can also offer scalable configurations that serve both discovery labs and commercial-scale operations, broadening addressable use cases.

Second, fortify consumable and reagent availability through diversified sourcing and strategic inventory agreements that prioritize continuity for high-value customers. Establishing multiple certified suppliers for critical components and negotiating tiered supply contracts with lead-time protections will help stabilize service levels and preserve customer trust. In parallel, invest in service infrastructure and training to ensure rapid field support, which is increasingly a differentiator in procurement decisions.

Third, expand software and analytics offerings to shift value capture beyond hardware. Integrated bioinformatics, validated data pipelines, and subscription-based visualization platforms improve user outcomes and increase customer stickiness. These digital offerings should be developed with regulatory traceability and auditability in mind to meet end-user compliance needs. Strategic partnerships or acquisitions of analytics specialists can accelerate capability build-out when organic development would be slower.

Fourth, adopt a regionally nuanced go-to-market posture that reflects the specific procurement patterns, regulatory requirements, and support expectations of each territory. Local partnerships, certification programs, and tailored financing solutions can lower adoption friction and foster deeper customer relationships. Lastly, incorporate trade-policy scenario planning into product and sourcing strategies. Establish cross-functional teams that continuously monitor tariff movements, negotiate flexible contracts, and model alternative manufacturing footprints to maintain resilience under varying policy regimes.

By implementing these actions, industry leaders can secure more predictable revenue streams, reduce operational vulnerability, and enhance their ability to meet the differentiated needs of research institutions, biotech innovators, CROs, and pharmaceutical developers.

A mixed-methods research approach combining primary stakeholder interviews, technical product reviews, and policy scanning to produce validated, actionable insights

This research synthesis is built from a triangulated methodology combining primary qualitative interviews, secondary literature synthesis, and targeted product and policy scans. Primary inputs include structured interviews with laboratory directors, procurement specialists, instrument engineers, and commercial leaders across academic, industrial, and service-provider segments. These discussions focused on procurement drivers, validation workflows, supply-chain sensitivities, and the role of data analytics in instrument adoption.

Secondary research comprised a review of technical whitepapers, regulatory guidance documents, patent filings, and industry briefings to contextualize trends in technology maturation and standardization. Industry product specifications and publicly available validation studies were analyzed to compare performance characteristics across instrument classes and to identify recurring pain points in sample preparation, throughput, and data handling. Policy and trade analyses were incorporated to assess how recent tariff measures and import controls influence sourcing decisions and manufacturing footprints.

Analytical approaches included cross-segmentation mapping to align instrument attributes with application needs and end-user procurement behavior, as well as scenario modeling to evaluate the operational impact of supply interruptions and policy shifts. Data validation steps involved corroborating primary interview themes with documentary evidence and seeking multiple independent confirmations for claims related to technology adoption and procurement timelines. Confidentiality safeguards were maintained to protect proprietary information shared by participants, and synthesized findings were normalized to avoid overreliance on single-source perspectives.

This mixed-method methodology yields a balanced view that integrates real-world operational insights with technical performance assessments and policy-awareness, providing decision-makers with actionable context rather than speculative forecasts.

Summative implications showing why workflow integration, supply resiliency, and data-centric services determine competitive success across the industry

In conclusion, the plant biotechnology equipment landscape is in the midst of a strategic inflection driven by technological maturation, evolving procurement expectations, and geopolitical trade considerations. Instrument innovation is converging with software-driven analytics and consumable-centric business models, shifting the competitive focus from point instruments to validated, end-to-end workflows that deliver reproducible outputs. This evolution favors vendors who can pair technical performance with robust service networks, validated protocols, and supply-chain resilience.

Trade-policy developments introduce a new imperative for manufacturers and buyers to design flexibility into sourcing and product architecture. While tariffs and related measures create short-term cost and timeline pressures, the longer-term response-diversified manufacturing, modular design, and tighter supplier partnerships-will determine which organizations can sustain performance and customer trust. Regional market dynamics further shape strategies, as diverse regulatory expectations and procurement behaviors require tailored go-to-market models.

Ultimately, stakeholders that align R&D investments, commercial models, and operational practices around workflow integration, data integrity, and resiliency will capture disproportionate value. The recommendations and insights presented here are intended to help executives prioritize actions that reduce risk, accelerate adoption, and strengthen their competitive position in an increasingly complex and opportunity-rich sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Plant Biotechnology Equipment Market, by Instrument Type

  • 8.1. Bioreactors
    • 8.1.1. Single Use
    • 8.1.2. Stainless Steel
  • 8.2. DNA Sequencers
    • 8.2.1. Next Generation Sequencing
    • 8.2.2. Sanger Sequencing
  • 8.3. Microarray Systems
    • 8.3.1. Gene Expression
    • 8.3.2. SNP Analysis
  • 8.4. PCR Systems

9. Plant Biotechnology Equipment Market, by Technology

  • 9.1. CRISPR Tools
    • 9.1.1. Plasmid Delivery
    • 9.1.2. Ribonucleoprotein
  • 9.2. Next Generation Sequencing
  • 9.3. PCR Technology

10. Plant Biotechnology Equipment Market, by Workflow Stage

  • 10.1. Analysis
    • 10.1.1. Bioinformatics
    • 10.1.2. Data Visualization
  • 10.2. Sample Preparation
    • 10.2.1. DNA Extraction
    • 10.2.2. Library Preparation
  • 10.3. Synthesis
    • 10.3.1. Gene Synthesis
    • 10.3.2. Oligo Synthesis

11. Plant Biotechnology Equipment Market, by Application

  • 11.1. Gene Editing
  • 11.2. Genetic Analysis
    • 11.2.1. Expression Analysis
    • 11.2.2. Genotyping
  • 11.3. Phenotyping
    • 11.3.1. Image Analysis
    • 11.3.2. Sensor Based
  • 11.4. Tissue Culture
    • 11.4.1. Callus Culture
    • 11.4.2. Protoplast Culture

12. Plant Biotechnology Equipment Market, by End User

  • 12.1. Academic Institutions
    • 12.1.1. Research Centers
    • 12.1.2. Universities
  • 12.2. Biotech Companies
    • 12.2.1. Agri Biotech
    • 12.2.2. Pharma Biotech
  • 12.3. Contract Research Organizations
  • 12.4. Pharma Companies

13. Plant Biotechnology Equipment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Plant Biotechnology Equipment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Plant Biotechnology Equipment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Plant Biotechnology Equipment Market

17. China Plant Biotechnology Equipment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. Bio-Rad Laboratories, Inc.
  • 18.7. Danaher Corporation
  • 18.8. LabRepCo
  • 18.9. LemnaTec GmbH
  • 18.10. LGC Limited
  • 18.11. Merck KGaA
  • 18.12. Microsil India Pvt. Ltd.
  • 18.13. Narang Scientific Works Pvt. Ltd.
  • 18.14. Neu-tec Group Inc.
  • 18.15. PerkinElmer, Inc.
  • 18.16. Sartorius AG
  • 18.17. Shimadzu Corporation
  • 18.18. Tecan Group Ltd.
  • 18.19. Thermo Fisher Scientific Inc.
  • 18.20. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SNP ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SNP ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SNP ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PLASMID DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PLASMID DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PLASMID DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RIBONUCLEOPROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RIBONUCLEOPROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RIBONUCLEOPROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DATA VISUALIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DATA VISUALIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DATA VISUALIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA EXTRACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA EXTRACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA EXTRACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY OLIGO SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY OLIGO SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY OLIGO SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY EXPRESSION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY EXPRESSION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY EXPRESSION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY IMAGE ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY IMAGE ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY IMAGE ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SENSOR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SENSOR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SENSOR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CALLUS CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CALLUS CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CALLUS CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PROTOPLAST CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PROTOPLAST CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PROTOPLAST CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY AGRI BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY AGRI BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY AGRI BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICR